Authors: | Houde, R. W.; Larouche Korn, S. J. |
Article Title: | Parenteral meptazinol: A US clinical trial |
Abstract: | The effectiveness and safety of i.m. meptazinol (50, 100, 200 mg), a unique μ1-selective opioid analgesic, was compared with i.m. morphine (4, 8 and 16 mg) in 128 cancer patients with moderate to severe postoperative pain; 102 patients completed the crossover study. The study design was a modification of the sequential, twin-crossover assay. Meptazinol was found to be one-fifteenth to one-twentieth as potent as morphine on a mg basis, and to provide a more rapid time to peak effect (about 40 min vs 1 h) than morphine. Morphine improved selected aspects of mood while meptazinol did not. Sleepiness was the most common side effect on morphine (n = 43), and nausea was most common on meptazinol (n = 35). The incidence of side effects appeared to be dose-related for both drugs. |
Keywords: | adolescent; adult; aged; major clinical study; clinical trial; drug efficacy; drug safety; side effect; comparative study; neurotoxicity; nausea; vomiting; dose-response relationship, drug; vasodilatation; central nervous system; time factors; abdominal pain; asthenia; confusion; gastrointestinal toxicity; psychological aspect; cardiovascular system; xerostomia; drug dose; morphine; somnolence; drug therapy; double-blind method; postoperative pain; pain, postoperative; morphine sulfate; euphoria; adverse drug reaction; mouth; therapy; mu opiate receptor; clinical trials; injections, intravenous; nervousness; muscle; nervous system; intramuscular drug administration; middle age; vertigo; sweating; intoxication; drug comparison; azepines; human; male; female; priority journal; meptazinol |
Journal Title: | Postgraduate Medical Journal |
Volume: | 61 |
Issue: | Suppl. 2 |
ISSN: | 0032-5473 |
Publisher: | BMJ Publishing Group Ltd. |
Date Published: | 1985-01-01 |
Start Page: | 17 |
End Page: | 22 |
Language: | English |
PUBMED: | 3909132 |
PROVIDER: | scopus |
DOI/URL: | |
Notes: | Article -- Export Date: 26 October 2021 -- Source: Scopus |